PLK1 and neoplasm: Similarly to the tumor growth inhibition observed in the U87MG‐Luc model, treatment with ANC@RNP/crEGFR‐PLK1 potently inhibited PDX tumor growth compared to the single gene editing treatments ANC@RNP/crEGFR and ANC@RNP/crPLK1, the non‐targeting group NC@RNP/crEGFR‐PLK1 or PBS controls (Figure 5b–d).